Loading
A phase 1/2 trial of PF-08634404 and Enfortumab vedotin in bladder & urothelial cancer, run by Pfizer, now recruiting.
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer is a phase 1/2 interventional study registered as NCT07421700 by Pfizer, with 132 participants planned, started 2026-03-11 and due to reach its primary completion in 2027-12-06. Interventions recorded: PF-08634404 and Enfortumab Vedotin.
Shares Enfortumab vedotin, Astellas, Muscle-invasive and advanced bladder cancer, Pfizer (incl. Seagen) and the tag pipeline.
Shares Enfortumab vedotin, Astellas, Muscle-invasive and advanced bladder cancer, Pfizer (incl. Seagen) and the tag pipeline.
Shares Enfortumab vedotin, Astellas, Pfizer (incl. Seagen), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Enfortumab vedotin, Astellas and the tag pipeline.